Akums Drugs & Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) that also operates domestic and international branded formulation businesses, trade generics, and API manufacturing. In FY26, the CDMO segment generated INR 3,485 crores in revenue, up 8.6% year on year, with an EBITDA margin of 14.4% in the fourth quarter. The company serves over 1,500 customers, including large Indian pharma companies and MNCs, and claims a leadership position in the Indian CDMO space. The overall adjusted EBITDA margin for FY26 was 12%, up from 11.2% in FY25, reflecting a mix of cost-plus CDMO contracts and higher-margin branded products. The competitive structure is fragmented, but Akums differentiates through regulatory approvals and long-standing customer relationships.
The persistence of these economics rests on qualification cycles and switching costs. Plant 2 received EU GMP accreditation in January 2026, and Plant 3 received ANVISA approval, enabling dossier filings across Europe and Brazil. The company has a fixed-price European CDMO contract worth EUR 35 million on a moving annual turnover basis, running until December 2032, which locks in revenue visibility. Customer audits and product registrations create high switching costs, as seen in the 15-year relationships with major clients. However, the API segment remains a drag, with FY26 EBITDA of negative INR 40 crores, and trade generics were deliberately scaled down to a negative INR 10 crores EBITDA. The moat is therefore specific to the CDMO and regulated-market businesses, not the entire portfolio.
The inflection point is now. Commercial supplies from the European contract are expected to commence in FY28, while Zambia supplies of $25 million per year from Indian facilities are slated to begin by the end of Q2 FY27. The Zambia local manufacturing facility, with a $45 million project cost and Akums holding 51%, is expected to start revenues in calendar year 2029. Newer facilities, including the injectable plant, Penem facility, and Baddi plant, are ramping up with client audits and product approvals in advanced stages. By mid-2028, the CDMO segment should be generating roughly INR 300 crores annually from the European contract and INR 200 crores from Zambia, on top of organic double-digit volume growth. The company guided to double-digit volume growth in H1 FY27, and the oral solids facility is being expanded to support 20%+ volume growth.
Management's track record is mixed but improving. In August 2025, they guided to mid-to-high single-digit CDMO revenue growth for FY26, and delivered 8.6% for the full year, slightly above the midpoint. They also promised a significant reduction in API losses, and while FY26 API EBITDA was still negative at INR 40 crores, they expect a sharp reduction in FY27 with a European audit upcoming. Capex has been consistent: INR 222 crores in FY26 and a target of INR 300 crores for FY27. The balance sheet is strong with INR 1,682 crores in cash and equivalents, and the board recommended a final dividend of INR 1 and a special dividend of INR 2 per share for FY26. The company has also committed to a tax rate of around 29% going forward, down from 32%.
The quantified earnings path depends on the execution of these contracts and the ramp-up of new capacity. The European contract provides fixed-price revenue until 2032, and Zambia supplies are committed for FY27 and FY28, giving high visibility. The key watchpoint is the API business, which has been loss-making for three years; management expects a significant reduction in losses in FY27, but the sustainability of recent API price increases is uncertain. Another risk is the working capital increase to 105 days from 91 days, driven by inventory buildup secured by advanced payments. If the European supplies slip or Zambia timelines extend, the revenue mix shift to regulated markets could be delayed. The falsifier would be a failure to reduce API losses or a delay in the European commercial supply start, which would undermine the margin expansion thesis.
companyname: Akums Drugs and Pharmaceuticals Limited ticker: AKUMS sector: Pharmaceuticals – CDMO (Contract Development and Manufacturing Organization) Akums is India's largest pharmaceutical CDMO (Contract Development and Manufacturing Organization), a claim the annual report supports on three metrics: revenue, production capacity, and number of clients served. Established in 2004, the company went public in 2024 (NSE/BSE ticker AKUMS) and operates 14 manufacturing facilities across Haridwar, ...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion
FY27 CDMO revenue growth guided at $25 million annually driven by Zambia project commercial supplies
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Akums Drugs & Pharmaceuticals Ltd. and 4,900+ companies.
5-day free pass. No card required.